Oncologie and Merck Collaborate to Evaluate Bavituximab + Keytruda for Treatment of Advanced Gastric or Gastroesophageal Cancer
Merck’s Zerbaxa (ceftolozane and tazobactam) Receives FDA’s Approval for Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia in Adults
Shots:
- Oncologie to conduct P-II study assessing the efficacy and safety of Bavituximab in combination with Merck’s Keytruda (pembrolizumab) in patients with 1L advanced gastric or gastroesophageal cancer enrolling ~80 patients in the US, UK, Korea and Taiwan with expected enrollment in H2’19
- The focus of the collaboration is to evaluate the combination Keytruda and Bavituximab for getting better insights of cancer further improving QoL
- Bavituximab is a chimeric mAb targeting the activity of phosphatidylserine (PS) and has shown safety and tolerability in multiple clinical trials. Keytruda is a mAb blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2 and activating the T lymphocytes and is evaluated in 950+ trials for multiple indications
Click here to read full press release/ article | Ref: PRNewswire | Image: Twitter